| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Neurology, Vol 48, Issue 6 1557-1565, Copyright © 1997 by American Academy of Neurology
ARTICLES |
G Giovannoni, M Lai, J Thorpe, D Kidd, V Chamoun, AJ Thompson, DH Miller, M Feldmann and EJ Thompson
Institute of Neurology, Department of Neuroimmunology, London, UK.
OBJECTIVE: To assess whether serial serum levels of soluble forms of intercellular adhesion molecule-1 (sICAM-1) and vascular cell adhesion molecule-1 (sVCAM-1) are useful as surrogate markers of disease activity in multiple sclerosis (MS). BACKGROUND: Increased levels of sICAM-1 and sVCAM-1 have been described in cross-sectional, but not longitudinal, studies of patients with MS. Although they appear to correlate with clinical and MRI markers of disease activity, their role as potential surrogate markers remains undefined. METHODS: Serial serum levels of sICAM-1 and sVCAM-1 were measured in patients with MS undergoing monthly gadolinium-enhanced MRI studies of the brain (462 gadolinium-enhanced MRI in 57 patients) and in 12 normal control subjects. Ten patients had primary progressive (PP), 22 relapsing remitting (RR), and 25 secondary progressive (SP) disease. RESULTS: Levels of sICAM-1 and sVCAM-1 were increased intermittently in patients with all subtypes of MS. Median levels of sICAM-1 were elevated in patients with MS compared with normal controls (normal controls median [interquartile range] = 176[119-209] compared with PP = 502[194-1768], RR = 419[158-481], and SP = 352[196-469] ng/mL; p = 0.04). After excluding patients with PP MS, patients with high sICAM-1 levels had a greater number of gadolinium-enhancing lesions per study (1.9[0.9-4.3]) than patients with normal levels (0.4[0-2.7], p = 0.03), and patients with MRI studies with no gadolinium-enhancing lesions had lower associated sICAM-1 levels (200 ng/mL[85-561]) than patients with only persistent (349 ng/mL[82-615]) or new enhancing lesions (497 ng/mL[108- 667], p = 0.03). Patients with RR or SP disease that progressed clinically during the study had a greater number of gadolinium- enhancing lesions per MRI study (3.5[0.4-5.5]) than did patients in whom disease did not progress (1.2 [0.3-2.7], p = 0.03). The patients with progressive disease tended to have higher sICAM-1 levels (469 ng/mL [196-1019]) than patients in whom disease did not progress (353 ng/mL [171-469], p = 0.07). Although MS patients tended to have higher sVCAM-1 levels than did normal controls, this finding was not significant. No correlation could be found between levels of sVCAM-1 and gadolinium enhancement on MRI. CONCLUSIONS: Patients with MS have elevated levels of sICAM-1, which correlate with gadolinium enhancement on MRI and possibly short-term disease progression. Soluble ICAM-1, and not sVCAM-1, may therefore be suitable as a long-term surrogate marker of disease activity in MS.
This article has been cited by other articles:
|
|
 |
|
  M. Ukkonen, X. Wu, B. Reipert, P. Dastidar, and I. Elovaara Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 701 - 707. [Abstract] [PDF]
|
|
|
|
|
|
C A B. Hashemi, Y C. Zang, J A Arbona, J A Bauerle, M L Frazer, H Lee, L Flury, E S Moore, M C Kolar, R Y Washington, et al. Serum immunologic markers in multiple sclerosis patients on continuous combined therapy with beta-interferon 1a, prednisone and azathioprine Multiple Sclerosis, September 1, 2006; 12(5): 652 - 658. [Abstract] [PDF]
|
|
|
|
|
|
V Yadav, G Marracci, J Lovera, W Woodward, K Bogardus, W Marquardt, L Shinto, C Morris, and D Bourdette Lipoic acid in multiple sclerosis: a pilot study Multiple Sclerosis, April 1, 2005; 11(2): 159 - 165. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Bielekova and R. Martin Development of biomarkers in multiple sclerosis Brain, July 1, 2004; 127(7): 1463 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Minagar and J S. Alexander Blood-brain barrier disruption in multiple sclerosis Multiple Sclerosis, December 1, 2003; 9(6): 540 - 549. [Abstract] [PDF]
|
|
|
|
 |
|
 Y Zoukos, T N Thomaides, D Kidd, M L Cuzner, and A Thompson Expression of {beta}2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study J. Neurol. Neurosurg. Psychiatry, February 1, 2003; 74(2): 197 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Buljevac, H. Z. Flach, W. C. J. Hop, D. Hijdra, J. D. Laman, H. F. J. Savelkoul, F. G. A. van der Meche, P. A. van Doorn, and R. Q. Hintzen Prospective study on the relationship between infections and multiple sclerosis exacerbations Brain, May 1, 2002; 125(5): 952 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Giovannoni, A. J. Thompson, D. H. Miller, and E. J. Thompson Fatigue is not associated with raised inflammatory markers in multiple sclerosis Neurology, August 28, 2001; 57(4): 676 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Duran, E M Martinez-Caceres, L Brieva, M Tintore, and X Montalban Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis Multiple Sclerosis, June 1, 2001; 7(3): 151 - 156. [Abstract] [PDF]
|
|
|
|
 |
|
 J. R. Avasarala, S. J. Khoury, and H. L. Weiner Surrogate Markers in Multiple Sclerosis Arch Neurol, May 1, 2001; 58(5): 834 - 834. [Full Text] [PDF]
|
|
|
|
|
|
N A Losseff, D H Miller, D Kidd, and A J Thompson The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results Multiple Sclerosis, February 1, 2001; 7(1): 23 - 25. [Abstract] [PDF]
|
|
|
|
|
|
I. Elovaara, M. Ukkonen, M. Leppakynnas, T. Lehtimaki, M. Luomala, J. Peltola, and P. Dastidar Adhesion Molecules in Multiple Sclerosis: Relation to Subtypes of Disease and Methylprednisolone Therapy Arch Neurol, April 1, 2000; 57(4): 546 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Duran, E. M. Martinez-Caceres, J. Rio, N. Barbera, M. E. Marzo, and X. Montalban Immunological profile of patients with primary progressive multiple sclerosis: Expression of adhesion molecules Brain, December 1, 1999; 122(12): 2297 - 2307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Waubant, D. E. Goodkin, L. Gee, P. Bacchetti, R. Sloan, T. Stewart, P.-B. Andersson, G. Stabler, and K. Miller Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis Neurology, October 22, 1999; 53(7): 1397 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Trojano, C. Avolio, G. M. Liuzzi, M. Ruggieri, G. Defazio, M. Liguori, M. P. Santacroce, D. Paolicelli, F. Giuliani, P. Riccio, et al. Changes of serum sICAM-1 and MMP-9 induced by rIFN{beta}-1b treatment in relapsing-remitting MS Neurology, October 22, 1999; 53(7): 1402 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Khoury, E. J. Orav, C. R. G. Guttmann, R. Kikinis, F. A. Jolesz, and H. L. Weiner Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis Neurology, September 1, 1999; 53(4): 758 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Surensen Biological markers in body fluids for activity and progression in multiple sclerosis Multiple Sclerosis, August 1, 1999; 5(4): 287 - 290. [Abstract] [PDF]
|
|
|
|
|
|
P. Rieckmann, B. Altenhofen, A. Riegel, B. Kallmann, and K Felgenhauer Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis Multiple Sclerosis, June 1, 1998; 4(3): 178 - 182. [Abstract] [PDF]
|
|
|
|
|
|
M Trojano, C Avolio, M Ruggieri, G Defazio, F Giuliani, D Paolicelli, and P Livrea Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFN{beta}-1b treatment Multiple Sclerosis, June 1, 1998; 4(3): 183 - 187. [Abstract] [PDF]
|
|
|
|
|
|
P. Stinissen, R. Medaer, and J. Raus Myelin reactive T cells in the autoimmune pathogenesis of multiple sclerosis Multiple Sclerosis, June 1, 1998; 4(3): 203 - 211. [Abstract] [PDF]
|
|
|
|
|
|
J D Laman, E J Thompson, and L Kappos Body fluid markers to monitor multiple sclerosis: the assays and the challenges Multiple Sclerosis, June 1, 1998; 4(3): 266 - 269. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
